Amgen Inc.

NASDAQ:AMGN

Drug Manufacturers - General

Healthcare
$443.89 -2.03%

-$6.93 today

Market cap
$240.11B
Beta
0.42
P/E (TTM)
23.2
EPS (TTM)
$14.44
Dividend yield
2.93%
52W Low $267.83High $391.29

Volume 2.58M

Average 2.76M

AMGN Weighted Avg Shares (Diluted)

Average shares outstanding including dilutive securities, used to calculate diluted EPS.

Amgen Inc.NASDAQ: AMGN

Weighted Avg Shares (Diluted) · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares (diluted) grows in line with its trailing trend

Q2 FY2026 weighted avg shares (diluted) of 544M shares rose 0.6% year over year, in line with the +0.3% change in trailing-twelve-month weighted avg shares (diluted). Sequentially, it rose 0.0% from the prior quarter. Over 3 fiscal years it compounded at +0.1% a year.

Context

  • Weighted avg shares (diluted) increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +0.6% holds above the trailing-twelve-month pace of +0.3%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
544M+0.0% QoQ
Last fiscal yearDec 2025
542M+0.2% YoY
LTMJun 2026
543.25M+0.3% YoY
Weighted Avg Shares (Diluted) past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+0.6%——
1 year+0.2%——
3-year CAGR+0.1%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares (Diluted) history

Shares · from the income statement

Latest · FY2025
542M USD
Year-over-year change
+0.2%
4-year CAGR
-1.4%

Weighted Avg Shares (Diluted) vs competitors

How AMGN compares with its peers on the latest reported figures

  • AMGN's LTM Jun 2026 weighted avg shares (diluted) of 543.25M shares is the lowest of the 10 companies compared; the peer median is 2.04B shares.
  • Its year-over-year change of +0.3% is the 3rd highest of 10, against a peer median of +0.0%.
  • Over three fiscal years its annual growth of +0.1% compares with a peer median of -0.5%.
AMGN Competitors Peer median
Weighted Avg Shares (Diluted) for AMGN and competitors
Company Period LTM YoY 3-year CAGR
PFEPfizer Inc.LTM Jun 20265.71B +0.0%-0.3%
MRKMerck & Co., Inc.LTM Jun 20262.48B -1.9%-0.5%
JNJJohnson & JohnsonLTM Sep 20262.44B +0.8%-3.0%
BMYBristol-Myers Squibb CompanyLTM Jun 20262.04B +0.3%-1.7%
GSKGSK plcLTM Jun 20262.04B -0.9%+0.3%
NVSNovartis AGLTM Jun 20261.92B -3.4%-3.8%
ABBVAbbVie Inc.LTM Sep 20261.77B +0.0%-0.1%
AZNAstraZeneca PLCLTM Sep 20261.56B +0.0%+0.0%
LLYEli Lilly and CompanyLTM Jun 2026896.6M -0.6%-1.9%
AMGNAmgen Inc.LTM Jun 2026543.25M +0.3%+0.1%
Peer median (excluding AMGN) 2.04B+0.0%-0.5%

Competitors are the stored peer set for AMGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue25.98B26.32B28.19B33.42B36.74B
Cost of Revenue6.45B6.41B8.42B12.86B10.73B
Gross Profit19.53B19.92B19.78B20.57B26.01B
Gross Margin75.2%75.7%70.1%61.5%70.8%
Research & Development6.32B4.43B4.78B5.96B6.97B
Selling, General & Admin5.37B5.41B6.18B7.1B7.05B
Operating Expenses11.89B10.35B11.84B13.31B15.34B
Depreciation & Amortization3.4B3.42B4.07B5.59B5.17B
EBITDA11.3B12.17B14.8B13.36B16.9B
EBITDA Margin43.5%46.2%52.5%40.0%46.0%
Operating Income7.64B9.57B7.9B7.26B10.68B
Operating Margin29.4%36.3%28.0%21.7%29.1%
Interest Income00000
Interest Expense1.2B1.41B2.88B3.16B2.76B
Other Income / Expenses(938M)(2.22B)(42M)(2.65B)(1.7B)
Income Before Tax6.7B7.35B7.86B4.61B8.98B
Pre-Tax Margin25.8%27.9%27.9%13.8%24.4%
Income Tax Expense808M794M1.14B519M1.27B
Net Income5.89B6.55B6.72B4.09B7.71B
Net Margin22.7%24.9%23.8%12.2%21.0%
EPS (Basic)10.3412.1812.567.6214.33
EPS (Diluted)10.2812.1112.497.5614.23
Weighted Avg Shares570M538M535M541M538M
Weighted Avg Shares (Diluted)573M541M538M541M542M

Amgen Inc.

NASDAQ:AMGN

Intrinsic Alpha fair value

Locked

Current Price

$443.89

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.